Cannabinoid Type-2 Receptor Agonist, JWH133 May Be a Possible Candidate for Targeting Infection, Inflammation, and Immunity in COVID-19

Cannabinoid Type-2 Receptor Agonist, JWH133 May Be a Possible Candidate for Targeting Infection, Inflammation, and Immunity in COVID-19

The COVID-19 pandemic, caused by SARS-CoV-2, is a deadly disease affecting millions due to the non-availability of drugs and vaccines. The majority of COVID-19 drugs have been repurposed based on antiviral, immunomodulatory, and antibiotic potential. The pathogenesis and advanced complications with...

Full description

Bibliographic Details
Main Authors: Niraj Kumar Jha, Charu Sharma, Mohamed Fizur Nagoor Meeran, Saurabh Kumar Jha, Vivek Dhar Dwivedi, Piyush Kumar Gupta, Abhijit Dey, Kavindra Kumar Kesari, Shreesh Ojha
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Immuno
Subjects:
cannabinoids
CB2 receptors
COVID-19
immunomodulators
inflammation
JWH133
Online Access:https://www.mdpi.com/2673-5601/1/3/20

Similar Items

Similar Items